Kandel Pujan, Wallace Michael B
Department of Gastroenterology and Hepatology Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Cancers (Basel). 2018 Feb 17;10(2):54. doi: 10.3390/cancers10020054.
Pancreas cancer is a lethal cancer as the majority patients are diagnosed at an advanced incurable stage. Despite improvements in diagnostic modalities and management strategies, including surgery and chemotherapies, the outcome of pancreas cancer remains poor. Endoscopic ultrasound (EUS) is an important imaging tool for pancreas cancer. For decades, resected pancreas cancer and other cancer specimens have been used to identify tissue biomarkers or genomics for precision therapy; however, only 20% of patients undergo surgery, and thus, this framework is not useful for unresectable pancreas cancer. With advancements in needle technologies, tumor specimens can be obtained at the time of tissue diagnosis. Tumor tissue can be used for development of personalized cancer treatment, such as performing whole exome sequencing and global genomic profiling of pancreas cancer, development of tissue biomarkers, and targeted mutational assays for precise chemotherapy treatment. In this review, we discuss the recent advances in tissue acquisition of pancreas cancer.
胰腺癌是一种致命的癌症,因为大多数患者在晚期无法治愈阶段才被诊断出来。尽管在诊断方式和管理策略(包括手术和化疗)方面有所改进,但胰腺癌的治疗结果仍然很差。内镜超声(EUS)是胰腺癌的一种重要成像工具。几十年来,已切除的胰腺癌和其他癌症标本一直被用于识别组织生物标志物或基因组学以进行精准治疗;然而,只有20%的患者接受手术,因此,这个框架对不可切除的胰腺癌并不适用。随着穿刺技术的进步,可以在组织诊断时获取肿瘤标本。肿瘤组织可用于开发个性化癌症治疗,例如对胰腺癌进行全外显子组测序和全基因组分析、开发组织生物标志物以及进行靶向突变检测以进行精确化疗。在这篇综述中,我们讨论了胰腺癌组织获取方面的最新进展。